Artivion, Inc. (AORT) Covered Calls

Artivion is a medical device company focused on developing innovative solutions for cardiac and vascular surgeons treating patients with aortic diseases. The firm manufactures and distributes a diverse portfolio of products, including aortic stent grafts, surgical sealants, and mechanical heart valves, alongside implantable human tissues. By addressing complex challenges in aortic repair, the company aims to improve clinical outcomes and simplify the most demanding surgical procedures worldwide.

You can sell covered calls on Artivion, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AORT (prices last updated Mon 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Artivion, Inc. (AORT) is a global medical technology leader dedicated to the "art" of aortic repair. Headquartered in Kennesaw, Georgia, the company rebranded from CryoLife in 2022 to reflect its singular focus on the aorta—the body’s main artery. Artivion provides a comprehensive suite of technologies that allow surgeons to treat life-threatening conditions such as aortic aneurysms and dissections with greater precision and reduced patient risk.

Core Business and Products

The company operates through four primary product pillars. Its Stent Grafts segment, bolstered by the acquisition of JOTEC, includes the E-vita and E-extra families used for complex aortic arch and abdominal repairs. The On-X Mechanical Heart Valves are renowned for being the only mechanical valves that allow patients to be managed with lower levels of blood thinners. Additionally, Artivion is a pioneer in Preservation Services, processing human cardiac and vascular tissues for transplant, and produces BioGlue, a surgical adhesive used in thousands of cardiovascular procedures annually to prevent internal bleeding.

Competitive Landscape

Artivion competes in the high-barrier-to-entry cardiovascular market against massive diversified healthcare conglomerates and specialized vascular firms. Key competitors include:

1. Edwards Lifesciences Corp.: A dominant force in structural heart therapy. Artivion differentiates itself by focusing specifically on the aortic arch and specialized mechanical valves, whereas this rival leads the market in transcatheter (TAVR) solutions.
2. Medtronic PLC: One of the world’s largest medical device companies. Artivion distinguishes itself through its "boutique" focus and proprietary tissue preservation services, which provide a biological alternative to the standardized synthetic grafts offered by this giant.
3. Abbott Laboratories: A major player in heart failure and structural heart. The company sets itself apart by its leadership in surgical sealants (BioGlue), a niche but essential surgical tool that complements rather than replaces this rival’s broader cardiac portfolio.
4. LeMaitre Vascular Inc.: A direct competitor in the vascular surgery space. Artivion differentiates by its heavy R&D investment in "Frozen Elephant Trunk" (FET) technology for aortic arch repair, a high-complexity segment where this rival has a smaller footprint.

Strategic Outlook and Innovation

The strategic roadmap for Artivion is centered on moving from a "tissue company" to a "high-growth device company." A major catalyst for 2026 is the anticipated FDA approval of the AMDS Hybrid Prosthesis, a unique device designed to treat acute Type A aortic dissections. Innovation also extends to the Arcevo LSA program, which aims to provide an off-the-shelf solution for total aortic arch replacement, potentially eliminating the need for custom-made grafts that currently require weeks of manufacturing lead time.

Future growth is supported by the company’s expansion into the Asia-Pacific market and the continued global "re-rating" of the On-X valve. As the global population ages and the prevalence of cardiovascular disease rises, Artivion is positioned as a pure-play infrastructure bet on the future of vascular surgery. By maintaining high-margin manufacturing and a direct sales force in over 100 countries, the firm aims to deliver consistent double-digit revenue growth while securing its status as the primary partner for the world’s leading aortic surgeons.

Want more examples? AOR Covered Calls | AOS Covered Calls